Evommune, Inc.: UBS initiates coverage with neutral rating and $8 target price
EVMN•UBS initiated coverage of Evommune with a neutral rating and an $8 target price.
Related News
Low-sulphur gasoil deliveries for October fall at expiry
USO•
Bristol Myers radiopharma cancer drug slows rare tumor progression in study
BMY•
Nasdaq trade halt: volatility trading pause at 10:21 a.m.
ALISU•
UBS initiates coverage of Mineralys Therapeutics with neutral rating and $29 target price
MLYS•
Nasdaq halts WFF trading for volatility at 9:38 a.m.
WFF•